Etanercept biosimilar - Sandoz

Drug Profile

Etanercept biosimilar - Sandoz

Alternative Names: Erelzi; GP 2015

Latest Information Update: 19 Jul 2017

Price : $50

At a glance

  • Originator Sandoz
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 27 Jun 2017 Registered for Ankylosing spondylitis in Iceland, Liechtenstein, Norway, European Union (SC)
  • 27 Jun 2017 Registered for Juvenile rheumatoid arthritis in Liechtenstein, Iceland, Norway, European Union (SC)
  • 27 Jun 2017 Registered for Plaque psoriasis (In children, In infants, In adolescents) in Norway (SC), Liechtenstein (SC), Iceland (SC), European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top